新周期 新技术 新生态！ 12月19日， 由起点锂电、起点储能、起点研究院SPIR主办的 2025起点用户侧储能及电池技术论坛 （ 同期： 2025 （第十届）起点锂电行业年会暨锂电金鼎奖颁奖典礼&起点研究十周年庆典）在深圳市维纳斯皇家酒店正式举办！现场 800+嘉宾参会，聚焦工 商业储能、便携式储能、户用储能、AIDC储能电池等核心议题，前瞻解析技术突破、破题安全挑战与价值链重构。 在下午的 AIDC数据中心储能及电池技术专场 ， 易事特 光储充事业部总经理 马强 发表了以《易事特风光储充一体化赋能 "AI+新能源"产业创 新发展 》为主题的演讲！ 以下为现场速记内容： 感谢各位嘉宾，感谢起点的邀请，很荣幸能和大家分享易事特集团在 AID C 和新能源两个板块的想法和方向。 我分享的主题是易事特风光储充一体化赋能 " AI+ 新能源"产业创新发展。 首先看下行业背景 ， AI 驱动能源需求，遇到了 3060 "双碳"能源转型的路径，这是国家两个 新型的 核心板块 顶层 政策。 2025 年 年初， 《能源法》针对新能源板块 做出了政策性的引导。 AI ， 应用于 各行各业，各种场景 ，与我们的生活息息相关。 ...

证券代码：000039、299901 证券简称：中集集团、中集 H 代 中国国际海运集装箱（集团）股份有限公司 投资者关系活动记录表 编号：2025-18 | □特定对象调研 | □分析师会议 | □媒体采访 | □业绩说明会 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 投 | 资 | 者 | 关 | 系 | 活 | □新闻发布会 | √路演活动 | 动类别 | | □现场参观 | □其他 | （请文字说明其他活动内容） | | | | | | | | 策略会：国泰海通策略会、华泰证券策略会、招商证券策略会、 | 参 | 与 | 单 | 位 | 名 | 称 | 东吴证券策略会、光大证券策略会 | | | 及人员姓名 | 一对一：中金公司、UBS | Securities | 瑞银证券、老虎环球基金、 | 广发基金、Capital | Group、永赢基金 | | | | | 时间 | 年 | 月 | 2025 | 11 | | | | | | 地点 | 中集集团总部、北京、深圳、上海 | | | | | | | | ...

Financial Data and Key Metrics Changes - The company reported a 12% increase in total sales for the second quarter, driven primarily by growth in the Climate Solutions segment [19] - Adjusted earnings per share (EPS) was $1.06, reflecting a 9% increase compared to the prior year [20] - The gross margin declined by 290 basis points to 22.3%, primarily due to increased costs associated with the data center capacity expansion [19][22] Business Line Data and Key Metrics Changes - Climate Solutions segment revenue increased by 24%, with data center sales growing by 42% [14][24] - Performance Technologies segment revenue declined by 4%, but adjusted EBITDA improved by 3%, with adjusted EBITDA margins increasing by 90 basis points to 14.7% [10][18] - HVAC Technologies revenue increased by 25% due to acquisitions, offset by lower indoor air quality sales [14] Market Data and Key Metrics Changes - The company anticipates a significant increase in data center sales, projecting over 60% growth for the fiscal year [8][24] - The company is expanding its manufacturing capacity in the U.S., U.K., and India to meet growing demand in the APAC region [7][8] Company Strategy and Development Direction - The company is focused on expanding its U.S. manufacturing capacity for data center products and investing in its fastest-growing businesses [3] - The strategy includes integrating recent acquisitions to improve margins and capacity utilization while unlocking new commercial opportunities [3][4] - The company aims to evolve from a low-volume, high-mix manufacturing operation to a high-volume producer, particularly in the data center segment [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet targets and customer commitments despite current challenges, including workforce hiring and training [7][9] - The company expects a significant jump in revenue between Q3 and Q4, driven by new capacity coming online [7][21] - Management raised the revenue outlook for fiscal 2026, expecting total company sales to grow in the range of 15%-20% [10][24] Other Important Information - Free cash flow was negative $31 million in the second quarter, primarily due to higher inventory builds and capital expenditures [22] - The company plans to fully fund its U.S. pension plan prior to a planned annuitization in the third quarter [26] Q&A Session Summary Question: Can you parse out year-over-year margin contraction on the climate side of the business? - The margin contraction was primarily driven by data center expansion costs, accounting for about 225-250 basis points, with additional impacts from HVAC Technologies and heat pump settlements [31][32] Question: What gives confidence that margins should normalize going into Q4? - Confidence stems from learning and efficiency improvements from previous product launches, which will help improve margins as production ramps up [50][51] Question: How do you view the total addressable market in calendar 2027? - The company anticipates that reaching $2 billion in sales by fiscal 2028 could represent 15%-20% of the available HVAC market [60] Question: How is customer concentration evolving in the data center area? - The company is building strong relationships with hyperscalers and neo-cloud providers, which is expected to drive further demand [86] Question: What is the outlook for liquid cooling business? - The liquid cooling market is evolving, and the company sees potential for growth in this area, complementing existing air cooling solutions [95]

Core Insights - Shenzhen Attom Technology has completed a Series A financing round of several tens of millions of RMB, exclusively funded by Qingsong Fund [1] - The raised funds will be primarily used for deepening overseas market expansion, innovation and iteration of core products such as liquid cooling temperature control for data centers, and attracting high-end global talent [1] Company Overview - Attom Technology was established in 2015 in Shenzhen, integrating R&D, manufacturing, sales, and services to create a complete micro-module data center product and thermal management platform for data centers and energy storage systems [1] - The company is led by founder Xu Gang, who has a significant background in global product platform R&D and has previously built a revenue-generating product line worth over 100 million RMB in a domestic listed company [1] - Attom's precision temperature control and modular data center products are currently deployed in over 70 countries and regions worldwide [1] Ownership Structure - Xu Gang holds 58.36% of the shares and controls 72.86% of the voting rights in Attom Technology [1]

Core Viewpoint - The company reported a decline in revenue and net profit for 1H25, primarily due to disruptions in orders and impairment losses, but new order growth and improved cash flow are promising for future performance [1][2]. Financial Performance - 1H25 revenue was 2.687 billion yuan, down 23% year-over-year, with a net profit of 338 million yuan, down 10.1% year-over-year [1]. - New orders in 1H25 reached 6 billion yuan, an increase of 89.5% year-over-year, with backlog orders at 10.6 billion yuan, up 20.4% year-over-year, marking a historical high [1]. Sector Performance - The biopharmaceutical sector saw revenue of 797 million yuan in 1H25, up 20% year-over-year, driven by successful project completions in North Africa [1]. - The green energy sector is expected to become a new growth driver, with 1H25 revenue from other fields at 288 million yuan, up 18% year-over-year [2]. Future Outlook - For 2H25, the company anticipates strong revenue growth, supported by a significant backlog of orders and a recovery in overseas CAPEX demand [2]. - The modular data center technology is expected to enhance collaboration with downstream operators, potentially driving mid-term growth [3]. Capacity Expansion - The company is expanding its international production capacity, with ongoing projects in Nantong, Malaysia, and potential new facilities in Thailand, which will support long-term growth [3]. Earnings Forecast - The company projects EPS of 0.61, 0.76, and 0.97 yuan for 2025-2027, with a target price of 13.41 HKD for 2025, reflecting an increase in the valuation due to the recovery in the pharmaceutical sector [3].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 13.41, up from a previous target of HKD 8.13 [6][5][7] Core Views - The company reported a revenue of RMB 2.687 billion in 1H25, a decrease of 23% year-over-year, and a net profit of RMB 338 million, down 10.1% year-over-year, primarily due to order disruptions at the end of 2024 and confirmed impairment losses on trade receivables, although other income related to subsidies increased [1][6] - New orders signed in 1H25 reached RMB 6 billion, representing a significant increase of 89.5% year-over-year, with a backlog of RMB 10.6 billion, up 20.4% year-over-year, marking a historical high [1][6] - The report anticipates a slight increase in net profit for 2025, driven by a reduction in impairment losses and a potential significant increase in new orders [1][5] Summary by Sections Medical Device Sector - The medical device sector achieved a revenue of RMB 2.687 billion in 1H25, down 23% year-over-year, with a net profit of RMB 338 million, down 10.1% year-over-year [1] - New orders in this sector were RMB 6 billion, up 89.5% year-over-year, with a backlog of RMB 10.6 billion, up 20.4% year-over-year [1] Pharmaceutical Sector - The biopharmaceutical sector generated revenue of RMB 797 million in 1H25, an increase of 20% year-over-year, mainly due to the successful completion of orders related to the first modular factory in North Africa [2] - The report expects strong revenue growth in the second half of 2025, supported by a robust order backlog and the recovery of overseas CAPEX demand [2] Chemical and Battery Materials Sector - The battery materials sector reported revenue of RMB 404 million in 1H25, down 38% year-over-year, with a backlog of RMB 760 million and new orders of RMB 290 million [3] - The chemical sector's revenue was RMB 581 million, down 17.5% year-over-year, with a backlog of RMB 1.03 billion and new orders of RMB 130 million [3] International Expansion - The report highlights the company's ongoing international capacity expansion, including the ramp-up of production at the Nantong factory and the expansion of the Malaysian factory [4] - Plans for a new production base in Thailand are also in progress to enhance the company's global supply chain [4] Profit Forecast and Valuation - The report projects EPS of RMB 0.61, 0.76, and 0.97 for 2025-2027, respectively, with a target price set at 20 times PE for 2025 [5][10] - The target price reflects an adjustment based on the recovery of the pharmaceutical sector's order capacity [5]

Core Viewpoint - SenSong International (02155) experienced a significant stock price increase of over 14% following the release of its interim results, indicating market confidence despite a decline in revenue and profit [1] Financial Performance - The company reported revenue of 2.687 billion RMB, a year-on-year decrease of 22.71% [1] - Shareholder profit was 338 million RMB, down 10.15% year-on-year [1] - The performance was in line with market expectations, attributed to a 9-14 month order confirmation cycle and a 23% decline in new orders last year, along with a 10% decrease in backlog orders [1] Order and Market Dynamics - New orders in the pharmaceutical sector reached 4.372 billion RMB, showing a remarkable year-on-year growth of 642%, exceeding expectations [1] - The backlog of orders stood at 10.566 billion RMB, reflecting a year-on-year increase of 20.4%, marking a historical high [1] Industry Trends - The company is advancing in high-tech industries such as AI, semiconductors, and pharmaceuticals [1] - In the pharmaceutical sector, there is a rapid increase in global capacity demand from MNCs and CXOs [1] - The AI sector is expected to see a new growth cycle in modular data centers [1] - The demand for high-end products in the wet electronic chemicals sector is driven by advancements in processes and growth in new energy requirements [1]

Group 1 - The company, Wanma Technology, has a diverse range of data center products in the communication equipment industry, including modular data centers, integrated data centers, and box-type data centers [2] - Fiber optics are widely used in the company's data center products within the communication equipment sector [2] - The company is currently delivering air-cooled equipment to customers and is developing liquid-cooled server cabinets [2]